Maintaining point of care testing capacity and pandemic preparedness in the post-COVID-19 era
INTRODUCTION: Testing at the point of care (we also refer to the 'point of need'), with rapid, actionable results reported to the patient and provider within hours can impact the individual as well as public health. Faster testing is good for patients and public health outcomes during 'peace time' (outside of the pandemic setting).
AREAS COVERED: Testing at the point of need was important during the COVID-19 pandemic to meet testing capacity demands, providing actionable results, and for providing testing within communities to increase access for all populations. Resources were acquired and built up dramatically during the pandemic as part of the response. With the end of the COVID-19 public health emergency and transition back to 'peace time' some testing sites have successfully shifted to using this capacity for testing for other critical needs, like sexually transmitted infection (STI) testing, and response to other seasonal diseases and for outbreak response.
EXPERT OPINION: The increased testing capacity added to handle unprecedented testing volume during the COVID-19 pandemic can be repurposed for other critical infectious diseases during 'peace time' (post-COVID-19 pandemic). This maintains testing capacity for the next pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert review of molecular diagnostics - 24(2024), 3 vom: 01. März, Seite 147-151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rakeman-Cagno, Jennifer L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737159.2023.2260743 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362212562 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362212562 | ||
| 003 | DE-627 | ||
| 005 | 20240325234301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737159.2023.2260743 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM362212562 | ||
| 035 | |a (NLM)37724428 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rakeman-Cagno, Jennifer L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Maintaining point of care testing capacity and pandemic preparedness in the post-COVID-19 era |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Testing at the point of care (we also refer to the 'point of need'), with rapid, actionable results reported to the patient and provider within hours can impact the individual as well as public health. Faster testing is good for patients and public health outcomes during 'peace time' (outside of the pandemic setting) | ||
| 520 | |a AREAS COVERED: Testing at the point of need was important during the COVID-19 pandemic to meet testing capacity demands, providing actionable results, and for providing testing within communities to increase access for all populations. Resources were acquired and built up dramatically during the pandemic as part of the response. With the end of the COVID-19 public health emergency and transition back to 'peace time' some testing sites have successfully shifted to using this capacity for testing for other critical needs, like sexually transmitted infection (STI) testing, and response to other seasonal diseases and for outbreak response | ||
| 520 | |a EXPERT OPINION: The increased testing capacity added to handle unprecedented testing volume during the COVID-19 pandemic can be repurposed for other critical infectious diseases during 'peace time' (post-COVID-19 pandemic). This maintains testing capacity for the next pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Point of care testing | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a point of need testing | |
| 650 | 4 | |a testing capacity | |
| 700 | 1 | |a Persing, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Loeffelholz, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of molecular diagnostics |d 2001 |g 24(2024), 3 vom: 01. März, Seite 147-151 |w (DE-627)NLM117852775 |x 1744-8352 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:147-151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737159.2023.2260743 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 3 |b 01 |c 03 |h 147-151 | ||